
BMRN Technical Analysis Summary (NASDAQ)
Analyze BMRN on the NASDAQ with RSI, MACD, ADX, Bollinger Bands, support, resistance, momentum, and the latest technical trading signals.
Disclaimer for Technical Analysis Page
The technical indicators and trading signals shown on this page are for informational purposes only and do not constitute financial advice. Stock market investments involve risk, and past performance is not a guarantee of future results. Always conduct your own research or consult a licensed financial advisor before making investment decisions.Read our Full DisclaimerBMRN Technical Analysis Summary (NASDAQ)
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock currently shows a bullish trend on the NASDAQ, supported by momentum and strong buying pressure.
Technical conditions suggest BioMarin Pharmaceutical Inc. on the NASDAQ is awaiting a decisive move. This mix signals that BioMarin Pharmaceutical Inc. is trading in a balanced range with no clear breakout yet.
RSI (14): 54.35
Stochastic %K: 73.81
Williams %R: -15.85
Rate of Change (ROC): 2.98
Takeaway:BioMarin Pharmaceutical Inc. shows strong bullish momentum, with buyers firmly in control.
MACD: -0.35
ADX: 24.71
ATR (14): 1.84
CCI (14): 100.49
Takeaway:BioMarin Pharmaceutical Inc. shows weakening trend signals, with bearish pressure building.
Takeaway:BioMarin Pharmaceutical Inc. trades closer to resistance, supported by stronger momentum within bands.
Takeaway:BioMarin Pharmaceutical Inc. trades above the trend line, showing healthy momentum within the channel.
Overall Takeaway:BMRN shows neutral money flow, with no clear directional pressure.
Bullish Signals
RSI above 50 → positive momentum from buyers.
ADX above 20 → strong underlying trend.
Price trading above middle Bollinger Band → mid-term support intact.
MFI below 80 → room for more buying without overbought risk.
Bearish Signals
Price near upper Bollinger Band → potential resistance and pullback risk.
RVI below 50 → vigor tilted toward sellers.
Overall Recommendation:Technical indicators for BioMarin Pharmaceutical Inc. are mixed, suggesting a Hold or wait-and-see approach.